Last updated: 2026-11-13 21:10:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Eli Lilly & Co. (LLY) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $1,443.79, with a market capitalization of $1.27T and a P/E ratio of 46.10. Over the past 52 weeks, its price has ranged from $850.51 to $1,460.00. This page covers its latest market performance, valuation, price trends and company information.
$1.27T | |
$1,429.91 | |
$1,449.52 | |
$1,420.95 | |
$1,427.28 | |
1.53M | |
2.55M | |
46.10 | |
$1,460.00 | |
$850.51 | |
0.47% | |
12-31 |
Eli Lilly & Co. (LLY) is trading at $1,445.74 in after-hours trading as of 2026-11-13 20:53:00, up 0.14% ($1.95) from the regular-session close of $1,443.79.
After-hours trading shows how investors are pricing LLY after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Eli Lilly & Co. (LLY) moved from $1,364.73 to $1,443.79, representing a gain of 5.79% ($79.06).
The stock traded between $1,333.22 and $1,460.00 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 2.86 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 97.3%
LLY is currently trading at $1,443.79, placing it 97.3% of the way from its 52-week low of $850.51 to its 52-week high of $1,460.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 50,000 |
| CEO | David A. Ricks |
| Founded | 1876 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for Eli Lilly & Co.
Dividend | |
|---|---|
| Ex-Dividend Date | Nov 13, 2026 |
| Payment Date | Dec 10, 2026 |
| Dividend Per Share | $1.73 |
Latest news related to Eli Lilly & Co. and LLY stock.
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 30.78% on an annualized basis producing an average annual return of 40.82%. Currently, Eli Lilly has a market capitalization of $1.27 trillion.
As tech stocks struggle post-election, investors are rotating into defensive sectors like healthcare. The State Street Healthcare Select Sector SPDR ETF (XLV) has gained 23% in 2026, outperforming the S&P 500's 11% return. Healthcare's inelastic demand makes it attractive during market volatility, though investors should consider dollar-cost averaging given the recent run-up.
Viking Therapeutics is conducting phase 3 trials for its obesity drug VK2735 in both injectable and oral forms. The oral formulation could expand the addressable market through a dual-dosing strategy. With conservative assumptions of 50% phase 3 success rate and 10% market share of tirzepatide's peak sales, Viking's stock could reach $110 per share by 2028, making a $10,000 investment worth up to $47,800.
Facility will manufacture injectable medicines, including retatrutideSite will create 850 high-wage jobs and 2,000 construction jobsINDIANAPOLIS, Nov. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today
AbbVie reported strong Q3 2026 results with immunology revenues rising 16.6% to $9.2 billion, driven by blockbuster drugs Skyrizi (up 22.9%) and Rinvoq (up 24.3%), offsetting Humira's 30.6% decline due to biosimilar competition. The company raised 2026 sales forecasts for both drugs, expecting combined growth exceeding 20%, with new indications in inflammatory bowel disease and dermatology providing additional growth opportunities.
Eligible investors can buy real shares of Eli Lilly & Co. (LLY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Browse other US stocks in the same sector as Eli Lilly & Co.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to LLY, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between LLY shares and USD.
LLY Shares to USD
1.00 LLY shares = 1,443.788 USD
Calculations are estimates based on the latest available price and are for reference only.
